Spinocerebellar Ataxia (SCA) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Spinocerebellar Ataxia (SCA) – Drugs In Development, 2024 report and make more profitable business decisions.
Spinocerebellar ataxias (SCAs) are a group of inherited conditions that affect the brain and spinal cord causing progressive difficulty with coordination. Symptoms include poor coordination, unsteady walk and a tendency to stumble, change in speech, and difficulty swallowing.
The Spinocerebellar Ataxia (SCA) drugs in development market research report provide comprehensive information on the therapeutics under development for Spinocerebellar Ataxia (SCA), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Spinocerebellar Ataxia (SCA) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Spinocerebellar Ataxia (SCA) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 38 molecules, with 31 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Spinocerebellar Ataxia (SCA) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Spinocerebellar Ataxia (SCA) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Spinocerebellar Ataxia (SCA) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Academia SinicaAnima Biotech Inc
Annji Pharmaceutical Co Ltd
Biohaven Ltd
Biorchestra Co Ltd
BioXcel Corp
Blade Therapeutics Inc
Celavie Biosciences LLC
Center of Molecular Immunology
Corestemchemon Inc
Enzerna Biosciences LLC
Everfront Biotech Inc
Exicure Inc
Gene Therapy Research Institution Co Ltd
Healx Ltd
IntraBio Ltd
Ionis Pharmaceuticals Inc
Kissei Pharmaceutical Co Ltd
Locanabio Inc
Mahzi Therapeutics Inc
Novartis AG
PTC Therapeutics Inc
Quiver Bioscience Inc
ReproCELL Inc
Sclnow Biotechnology Co Ltd
Seelos Therapeutics
Inc.
Shionogi & Co Ltd
Steminent Biotherapeutics Inc
The Chinese University of Hong Kong
The Scripps Research Institute
Triplet Therapeutics Inc
Universidade do Minho
University of Florida
University of Oxford
Vico Therapeutics BV
Vybion Inc
Wave Life Sciences Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Spinocerebellar Ataxia (SCA) reports